OPKO Health
OPK · Nasdaq · United States
Share price · OPK
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when OPK's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 15 Oct 2026+17.5%
- 29 Jul 2026-17.3%
Nothing announced by OPK that day or the session before.
- 28 Jul 2026+33.1%
- 13 Jul 2026-8.9%
Nothing announced by OPK that day or the session before.
- 28 May 2026+10.0%
Nothing announced by OPK that day or the session before.
- 20 May 2026+7.0%
Nothing announced by OPK that day or the session before.
- 18 May 2026+2.7%
Nothing announced by OPK that day or the session before.
- 29 Apr 2026-8.3%
- 6 Apr 2026+3.5%
Nothing announced by OPK that day or the session before.
- 2 Mar 2026+3.3%
Nothing announced by OPK that day or the session before.
Share of unusual movement by asset
For each asset, the share of OPK's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
Extended-release calcifediol (Rayaldee)events and moves
| 1 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 0% |
| Other company news (earnings, financing, releases naming no asset) | — | 37% |
| Sessions with no dated event | — | 63% |
Assets
(3 total)
| Target & Modality | |||
|---|---|---|---|
Extended-release calcifediol(Rayaldee) | Approved | Vitamin D receptor (VDR), via conversion to calcitriolSmall molecule | Chronic Kidney Disease Secondary Hyperparathyroidism |
somatrogon(NGENLA) | Approved | Growth hormone receptorProtein / enzyme therapeutic | Growth Hormone Deficiency |
| Phase 1/2 | GLP-1/glucagon receptor (dual) | MASH / NASH |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (2)
October 2027 (1)
What to watch
Financial reports
Quarterly & interim (21)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $65M | $32M | $403M | $54M-$36M operating cash flow | report ↗ |
View 20 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $164M | $33M | $314M | $8.4M-$44M operating cash flow | report ↗ |
| 2026-Q1 | $124M | $29M | $356M | $55M-$19M operating cash flow | report ↗ |
| 2025-Q4 | $148M | — | $383M | $31M-$26M operating cash flow | report ↗ |
| 2025-Q3 | $152M | $30M | $429M | —-$35M operating cash flow | report ↗ |
| 2025-Q2 | $157M | $30M | $285M | $148M-$83M operating cash flow | report ↗ |
| 2025-Q1 | $150M | $31M | $450M | $68M-$35M operating cash flow | report ↗ |
| 2024-Q4 | $184M | — | $446M | —-$44M operating cash flow | report ↗ |
| 2024-Q3 | $174M | $29M | $420M | —-$77M operating cash flow | report ↗ |
| 2024-Q2 | $182M | $24M | $41M | $10M-$26M operating cash flow | report ↗ |
| 2024-Q1 | $174M | $22M | $76M | $82M-$36M operating cash flow | report ↗ |
| 2023-Q4 | $182M | — | $96M | $66M-$38M operating cash flow | report ↗ |
| 2023-Q3 | $179M | $19M | $139M | $84M$33M operating cash flow | report ↗ |
| 2023-Q2 | $265M | $18M | $108M | $20M-$0.4M operating cash flow | report ↗ |
| 2023-Q1 | $238M | $33M | $111M | $18M-$23M operating cash flow | report ↗ |
| 2022-Q4 | $185M | — | $153M | $85M-$32M operating cash flow | report ↗ |
| 2022-Q3 | $180M | $19M | $181M | $86M-$32M operating cash flow | report ↗ |
| 2022-Q2 | $310M | $17M | $210M | $102M-$11M operating cash flow | report ↗ |
| 2022-Q1 | $329M | $18M | $102M | $55M-$20M operating cash flow | report ↗ |
| 2021-Q4 | $401M | — | $135M | $74M-$5.6M operating cash flow | report ↗ |
| 2021-Q3 | $386M | $18M | $149M | —$33M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $607M | $124M | $383M | $56M-$179M operating cash flow | report ↗ |
OPKO Health reported full-year 2025 revenue of $606.88M, down 14.9% YoY, with R&D spend of $124.03M, up 17.9% YoY. Cash and equivalents were $382.74M, and the company reported a net loss of $225.68M.
Management introduced 2026 guidance for total revenues of $125M–$140M in Q1 and $530M–$560M for the full year, with total costs and expenses of $170M–$180M and $725M–$750M, respectively, and R&D included in costs of $30M–$32M and $125M–$135M. Key developments included a new Regeneron collaboration for multispecific antibodies, completion of Merck’s Phase 1 Epstein-Barr virus vaccine trial, FDA clearance to proceed for MDX2301, Australian Phase 1 approval for MDX2003, ongoing advancement of MDX2001 and MDX2004, and an expanded Entera Bio partnership for an oral PTH tablet program.
Insider transactions
Open-market activity, trailing 12 months: 6 purchases ($780K), 2 sales ($25K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-05 | PAGANELLI JOHN A · director | Open-market sale | 4,426 | $1.78 | $8K | Form 4 |
| 2026-11-05 | PAGANELLI JOHN A · director | Open-market sale | 9,175 | $1.82 | $17K | Form 4 |
| 2026-07-24 | Rubin Steven D · director, Executive VP-Administration | Tax withholding | 53,266 | $1.22 | $65K | Form 4 |
| 2026-07-24 | Logal Adam · Sr. Vice President, CFO | Tax withholding | 53,266 | $1.22 | $65K | Form 4 |
| 2026-06-18 | Yu Alice Lin-Tsing · director | Award / grant (derivative) | 30,000 | — | — | Form 4 |
| 2026-06-18 | UPPALURI SUBBARAO V · director | Award / grant (derivative) | 80,000 | — | — | Form 4 |
| 2026-06-18 | PFENNIGER RICHARD C JR · director | Award / grant (derivative) | 60,000 | — | — | Form 4 |
| 2026-06-18 | PAGANELLI JOHN A · director | Award / grant (derivative) | 30,000 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 232 reporting institutions held 200.8M shares ($227.3M, 27.0% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | Rubric Capital Management LP | 47,791,243 | $54.5M |
| 2 | BlackRock, Inc. | 36,232,223 | $41.3M |
| 3 | VANGUARD PORTFOLIO MANAGEMENT LLC | 14,769,719 | $16.8M |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 14,499,164 | $16.5M |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 11,301,501 | $12.9M |
| 6 | STATE STREET CORP | 9,501,377 | $10.8M |
| 7 | GOLDMAN SACHS GROUP INC | 7,675,026 | $8.7M |
| 8 | UBS Group AG | 6,071,432 | $6.9M |
| 9 | Whitefort Capital Management, LP | 4,253,340 | $4.8M |
| 10 | NORTHERN TRUST CORP | 3,619,346 | $4.1M |
| 11 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 3,574,039 | $4.1M |
| 12 | VANGUARD FIDUCIARY TRUST CO | 2,742,017 | $3.1M |
| 13 | AWM Investment Company, Inc. | 2,100,000 | $2.4M |
| 14 | CITADEL ADVISORS LLC | 2,079,547 | $2.4M |
| 15 | DIMENSIONAL FUND ADVISORS LP | 1,560,000 | $1.8M |